A Phase 1/2 interventional study of Ociperlimab and Tislelizumab in Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma, sponsored by BeiGene. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines — 3 open to participants now, 3 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · BeOne Medicines.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1/2, and was the 7th registered.
1,870 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →3 of the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
BeOne Medicines
Ages 18+
BeOne Medicines
Ages 18+
By country, each count listing its studies:
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6
First in 2017; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 66 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
1 of the studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed DLBCL NOS (Not Otherwise Specified), Epstein-Barr virus (EBV) + DLBCL NOS, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma [DHL/THL]), based on the World Health Organization (WHO) 2016 classification of tumors of hematopoietic and lymphoid tissue
disease before study entry, defined as either:
Exclusion Criteria:
Receipt of the following treatment:
Active diseases or history of autoimmune diseases that may relapse, with the following exceptions:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ociperlimab 900 mg and tislelizumab 200 mg every three weeks (Q3W) by intravenous injection (IV) until confirmed progressive disease, death, withdrawal of consent, loss of follow-up, or the end of study.
Drug: Ociperlimab · Drug: Tislelizumab
Participants received ociperlimab 900 mg and rituximab 375 mg/m² Q3W by intravenous injection until confirmed progressive disease, death, withdrawal of consent, loss of follow-up, or the end of study.
Drug: Ociperlimab · Drug: Rituximab
administered intravenously
Also known as: BGB-A1217
Administered intravenously once every 3 weeks
Also known as: BGB-A317, Tevimbra
Administered intravenously once every 3 weeks
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug(s), whether considered related to study drug(s) or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).
Time frame: From first dose of study drug up to 30 days after last dose, maximum time on treatment was 98 weeks.
Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33.3%
Time frame: 21 days
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDGPET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Complete Response Rate (CRR)
CRR is defined as the percentage of participants who achieved a complete response per the Lugano Classification (2014) as assessed by the investigator.
Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Duration of Response (DOR)
DOR is defined as the time from the date that response criteria were first met to the date that progressive disease is objectively documented per Lugano Classification (2014), as assessed by the investigator, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.
Time frame: Up to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Time to Response (TTR)
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) per Lugano Classification (2014) as assessed by the investigator
Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Progression-free Survival (PFS)
PFS is defined as the time from first dose until first documentation of progression per Lugano Classification (2014), as assessed by the investigator, or death, whichever comes first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Overall Survival (OS)
OS is defined as the time from first study drug administration to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From first dose of study drug to the data cutoff date of 30 August 2024; maximum time on study was 28 months.
Serum Concentration of Ociperlimab
Time frame: Predose and end of infusion (EOI) on Cycle 1 Day 1 (C1D1), Cycle 2 Day 1, Cycle 5 Day 1, Cycle 9 Day 1, and Cycle 17 Day 1
Host Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab
The number of participants with anti-drug antibodies to ociperlimab includes participants that were ADA-negative at Baseline and ADA-positive after drug administration during the treatment or follow-up observation period and participants who were positive at Baseline for ADA and with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period.
Time frame: From first dose of study treatment to 30 days after last dose; maximum time on treatment was 98 weeks
The study began in April 2022 and completed in August 2024. Fifty-three participants were enrolled in this study, and all received treatment.
| Milestone | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Started | 24 | 29 |
| Completed | 0 | 0 |
| Not completed | 24 | 29 |
| Withdrew: Death | 13 | 14 |
| Withdrew: Study ended by sponsor | 9 | 13 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug(s), whether considered related to study drug(s) or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).
| Participants | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Treatment Emergent Adverse Events | 24 | 28 |
| Serious Adverse Events | 9 | 8 |
The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33.3%
| mg Q3W | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Recommended Phase 2 Dose (RP2D) of Ociperlimab When Administered in Combination With Tislelizumab or Rituximab | 900 | 900 |
ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) based on the Lugano classification as assessed by the investigator. Response was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDGPET). CR: complete metabolic (no/minimal FDG uptake and no evidence of FDG-avid disease in bone marrow) and radiologic response (target lesions regressed to ≤ 1.5 cm in longest diameter with no extra-lymphatic sites of disease, no organ enlargement and normal bone marrow morphology), no new lesions, and no bone marrow involvement confirmed by bone marrow biopsies (if bone marrow was involved at baseline). PR is partial metabolic (reduced FDG uptake from Baseline) and radiologic response (≥ 50% decrease in size of measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \> 50% in length beyond normal) and no new lesions.
| percentage of participants | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Overall Response Rate (ORR) | 17.4 (5.0 to 38.8) | 18.5 (6.3 to 38.1) |
CRR is defined as the percentage of participants who achieved a complete response per the Lugano Classification (2014) as assessed by the investigator.
| percentage of participants | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Complete Response Rate (CRR) | 13.0 (2.8 to 33.6) | 7.4 (0.9 to 24.3) |
DOR is defined as the time from the date that response criteria were first met to the date that progressive disease is objectively documented per Lugano Classification (2014), as assessed by the investigator, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.
| Months | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Duration of Response (DOR) | 13.34 (6.2 to 18.7) | 7.82 (0.0 to 8.5) |
TTR is defined as the time from study treatment start to date of the earliest qualifying response (partial response or better) per Lugano Classification (2014) as assessed by the investigator
| months | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Time to Response (TTR) | 2.09 (2.07 to 2.17) | 2.04 (1.97 to 2.40) |
PFS is defined as the time from first dose until first documentation of progression per Lugano Classification (2014), as assessed by the investigator, or death, whichever comes first. Median PFS was estimated using the Kaplan-Meier method.
| Months | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Progression-free Survival (PFS) | 1.2 (0.9 to 1.9) | 1.8 (0.9 to 2.2) |
OS is defined as the time from first study drug administration to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
| Months | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Overall Survival (OS) | 13.2 (4.4 to NA) | 13.3 (4.9 to NA) |
| μg/mL | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Predose C1D1 | NA ± NA | NA ± NA |
| EOI C1D1 | 323.96 ± 21.810 | 296.48 ± 18.832 |
| Predose C2D1 | 61.84 ± 36.832 | 63.68 ± 38.413 |
| EOI C2D1 | 371.62 ± 24.589 | 389.27 ± 18.555 |
| Predose C5D1 | 127.20 ± 45.138 | 184.09 ± 27.675 |
| EOI C5D1 | 450.52 ± 10.707 | 507.48 ± 15.295 |
| Predose C9D1 | 181.58 ± 46.927 | 184.83 ± 23.101 |
| Predose C17D1 | 320.00 | — |
The number of participants with anti-drug antibodies to ociperlimab includes participants that were ADA-negative at Baseline and ADA-positive after drug administration during the treatment or follow-up observation period and participants who were positive at Baseline for ADA and with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period.
| Participants | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Host Immunogenicity: Number of Participants With Anti-drug Antibodies (ADA) to Ociperlimab | 0 | 1 |
Collected over All-cause mortality was assessed from enrollment through the end of the study, maximum time on study was 28 months. Adverse events were assessed from first dose of study treatment to 30 days after last dose; maximum time on treatment was 98 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ociperlimab + Tislelizumab | 13/24 (54.2%) | 9/24 (37.5%) | 23/24 (95.8%) |
| Ociperlimab + Rituximab | 14/29 (48.3%) | 8/29 (27.6%) | 28/29 (96.6%) |
| Event | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/24 | 0/29 |
| ConstipationGastrointestinal disorders | 1/24 | 0/29 |
| DeathGeneral disorders | 1/24 | 0/29 |
| Oedema peripheralGeneral disorders | 1/24 | 0/29 |
| BacteraemiaInfections and infestations | 1/24 | 0/29 |
| Herpes zosterInfections and infestations | 1/24 | 0/29 |
| Oral infectionInfections and infestations | 1/24 | 0/29 |
| Neutrophil count decreasedInvestigations | 1/24 | 1/29 |
| ShockVascular disorders | 1/24 | 0/29 |
| AnaemiaBlood and lymphatic system disorders | 0/24 | 1/29 |
| Event | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab |
|---|---|---|
| Neutrophil count decreasedInvestigations | 7/24 | 9/29 |
| White blood cell count decreasedInvestigations | 7/24 | 7/29 |
| AnaemiaBlood and lymphatic system disorders | 4/24 | 8/29 |
| Lymphocyte count decreasedInvestigations | 6/24 | 5/29 |
| Platelet count decreasedInvestigations | 1/24 | 7/29 |
| Blood lactate dehydrogenase increasedInvestigations | 5/24 | 6/29 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/24 | 6/29 |
| RashSkin and subcutaneous tissue disorders | 1/24 | 6/29 |
| PyrexiaGeneral disorders | 4/24 | 4/29 |
| HypokalaemiaMetabolism and nutrition disorders | 4/24 | 3/29 |
Safety Analysis Set
| Age, Continuous(Years) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| Median | 64.0 (40 to 79) | 66.0 (21 to 80) | 65.0 (21 to 80) |
| Sex: Female, Male(Participants) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| Female | 14 | 13 | 27 |
| Male | 10 | 16 | 26 |
| Race/Ethnicity, Customized(Participants) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| Asian | 24 | 29 | 53 |
| Region of Enrollment(participants) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| China | 24 | 29 | 53 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| Grade 0 | 8 | 8 | 16 |
| Grade 1 | 16 | 21 | 37 |
| Grade 2 | 0 | 0 | 0 |
| Weight(kg) | Ociperlimab + Tislelizumab | Ociperlimab + Rituximab | Total |
|---|---|---|---|
| Median | 59.00 (45.5 to 102.0) | 63.80 (45.0 to 90.0) | 62.00 (45.0 to 102.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Apr 2022 to primary completion in Aug 2024, 28 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 28 months is below that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Lymphoma, Large B-Cell, Diffuse →